ClinicalTrials.gov record
Terminated Phase 3 Interventional

A Clinical Trial Comparing Torcetrapib/Atorvastatin To Simvastatin In Subjects With High Cholesterol (A5091031).

ClinicalTrials.gov ID: NCT00267280

Public ClinicalTrials.gov record NCT00267280. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Apr 27, 2026, 6:20 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Open-Label, Multisite, Randomized, Parallel Group Study of the Efficacy and Safety of Fixed Combination Torcetrapib/Atorvastatin Administered Once Daily (QD) Compared to Simvastatin for 6 Weeks in Subjects With Hypercholesterolemia (A5091031)

Study identification

NCT ID
NCT00267280
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 3
Lead sponsor
Pfizer
Industry
Enrollment
640 participants

Conditions and interventions

Interventions

  • simvastatin Drug
  • torcetrapib/atorvastatin Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 31, 2005
Primary completion
Nov 30, 2006
Completion
Nov 30, 2006
Last update posted
Feb 16, 2012

2006

United States locations

U.S. sites
51
U.S. states
24
U.S. cities
51
Facility City State ZIP Site status
Pfizer Investigational Site Birmingham Alabama
Pfizer Investigational Site Mesa Arizona
Pfizer Investigational Site Alhambra California
Pfizer Investigational Site Inglewood California
Pfizer Investigational Site Los Angeles California
Pfizer Investigational Site Santa Ana California
Pfizer Investigational Site Wilmington Delaware
Pfizer Investigational Site Fort Lauderdale Florida
Pfizer Investigational Site Hollywood Florida
Pfizer Investigational Site Jacksonville Florida
Pfizer Investigational Site Merritt Island Florida
Pfizer Investigational Site Pensacola Florida
Pfizer Investigational Site Vero Beach Florida
Pfizer Investigational Site Winter Park Florida
Pfizer Investigational Site Atlanta Georgia
Pfizer Investigational Site Conyers Georgia
Pfizer Investigational Site Woodstock Georgia
Pfizer Investigational Site Hinsdale Illinois
Pfizer Investigational Site La Grange Illinois
Pfizer Investigational Site Park Ridge Illinois
Pfizer Investigational Site Springfield Illinois
Pfizer Investigational Site Kansas City Kansas
Pfizer Investigational Site Lexington Kentucky
Pfizer Investigational Site Baltimore Maryland
Pfizer Investigational Site Bethesda Maryland
Pfizer Investigational Site Elkton Maryland
Pfizer Investigational Site Flint Michigan
Pfizer Investigational Site Springfield Missouri
Pfizer Investigational Site Lawrenceville New Jersey
Pfizer Investigational Site Albany New York
Pfizer Investigational Site Seaford New York
Pfizer Investigational Site Charlotte North Carolina
Pfizer Investigational Site Cincinnati Ohio
Pfizer Investigational Site Mansfield Ohio
Pfizer Investigational Site Hillsboro Oregon
Pfizer Investigational Site Beaver Pennsylvania
Pfizer Investigational Site Flourtown Pennsylvania
Pfizer Investigational Site Philadelphia Pennsylvania
Pfizer Investigational Site Yardley Pennsylvania
Pfizer Investigational Site Greenville South Carolina
Pfizer Investigational Site Collierville Tennessee
Pfizer Investigational Site Kingsport Tennessee
Pfizer Investigational Site Knoxville Tennessee
Pfizer Investigational Site North Richland Hills Texas
Pfizer Investigational Site Spring Texas
Pfizer Investigational Site Salt Lake City Utah
Pfizer Investigational Site West Jordan Utah
Pfizer Investigational Site Richmond Virginia
Pfizer Investigational Site Bellevue Washington
Pfizer Investigational Site Puyallup Washington
Pfizer Investigational Site Tacoma Washington

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00267280, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 16, 2012 · Synced Apr 27, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00267280 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →